Hongyuan Xu, Yingxi Yang, Qiuxia Zhou, Ran Huo, Shaozhi Zhao, Yingfan Sun, Jie Wang, Qiheng He, Qifeng Yu, Jinyi Tang, Yuming Jiao, Jiguang Wang, Yong Cao
{"title":"<i>Map3k3 </i> <sup>I441M</sup> Knock-In Mouse Model of Cerebral Cavernous Malformations.","authors":"Hongyuan Xu, Yingxi Yang, Qiuxia Zhou, Ran Huo, Shaozhi Zhao, Yingfan Sun, Jie Wang, Qiheng He, Qifeng Yu, Jinyi Tang, Yuming Jiao, Jiguang Wang, Yong Cao","doi":"10.1161/STROKEAHA.124.049935","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cerebral cavernous malformations (CCMs) refer to vascular dysplasia primarily found in the brain, affecting ≈0.5% of the population. A somatic <i>Map3k3</i><sup>I441M</sup> mutation has been found in ≈40% of patients with sporadic CCMs, which were typically accompanied by somatic gain-of-function mutations in <i>PIK3CA</i>. Although mouse models of adeno-associated virus-BR1-mediated mutant overexpression have been reported, these models have limitations in representing clinical specimens of CCMs, which typically harbor single allele mutation in <i>Map3k3</i>. A <i>Map3k3</i><sup>I441M</sup> knock-in murine model of CCMs has not yet been established.</p><p><strong>Methods: </strong>The <i>Map3k3</i><sup>I441M</sup> knock-in mice were crossed with <i>Cdh5</i>-creER<sup>T2</sup> mice to induce mutant gene expression specifically in endothelial cells. Subsequently, <i>Map3k3</i><sup>I441M</sup> mice were bred with <i>Pten</i><sup>fl/fl</sup> mice to generate <i>Map3k3</i><sup>I441M</sup>; <i>Pten</i><sup>fl/fl</sup> mice. In both murine models, CCM lesions were examined using magnetic resonance imaging, while single-cell RNA sequencing and immunostaining were utilized to investigate the pathomechanism of the mutation. Finally, we administered an mTOR (mechanistic target of rapamycin) inhibitor to explore its therapeutic effect on lesions of both murine models.</p><p><strong>Results: </strong>Both endothelial <i>Map3k3</i><sup>I441M</sup> mutant juvenile mice and <i>Map3k3</i><sup>I441M</sup>; <i>Pten</i><sup>fl/fl</sup> mice developed abnormal lesions with human CCM characteristics. In <i>Map3k3</i><sup>I441M</sup> mice, the mutant promoted endothelial apoptosis, while activation of the PI3K (phosphatidylinositol 3-kinase) pathway was able to activate the downstream AKT (protein kinase B)/mTOR/p-S6 (phosphorylated S6 ribosomal protein) pathway and upregulate VEGFA (vascular endothelial growth factor A) expression, counteracting apoptosis, and facilitating lesion progression. The activation of PI3K signaling is required for <i>Map3k3</i><sup>I441M</sup> to generate CCM-like lesions in adult mice. Finally, we demonstrated that rapamycin effectively inhibited the formation of lesions in the <i>Map3k3</i><sup>I441M</sup> mice and <i>Map3k3</i><sup>I441M</sup>; <i>Pten</i><sup>fl/fl</sup> mice.</p><p><strong>Conclusions: </strong><i>Map3k3</i><sup>I441M</sup> heterozygous is sufficient to induce lesions in juvenile mice, while the additional activation of PI3K signaling is required for the effective formation of CCMs at the adult stage. The <i>Map3k3</i><sup>I441M</sup> murine model provides a preclinical model for further mechanistic and therapeutic studies of CCMs.</p>","PeriodicalId":21989,"journal":{"name":"Stroke","volume":"56 4","pages":"1010-1025"},"PeriodicalIF":7.8000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stroke","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1161/STROKEAHA.124.049935","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Cerebral cavernous malformations (CCMs) refer to vascular dysplasia primarily found in the brain, affecting ≈0.5% of the population. A somatic Map3k3I441M mutation has been found in ≈40% of patients with sporadic CCMs, which were typically accompanied by somatic gain-of-function mutations in PIK3CA. Although mouse models of adeno-associated virus-BR1-mediated mutant overexpression have been reported, these models have limitations in representing clinical specimens of CCMs, which typically harbor single allele mutation in Map3k3. A Map3k3I441M knock-in murine model of CCMs has not yet been established.
Methods: The Map3k3I441M knock-in mice were crossed with Cdh5-creERT2 mice to induce mutant gene expression specifically in endothelial cells. Subsequently, Map3k3I441M mice were bred with Ptenfl/fl mice to generate Map3k3I441M; Ptenfl/fl mice. In both murine models, CCM lesions were examined using magnetic resonance imaging, while single-cell RNA sequencing and immunostaining were utilized to investigate the pathomechanism of the mutation. Finally, we administered an mTOR (mechanistic target of rapamycin) inhibitor to explore its therapeutic effect on lesions of both murine models.
Results: Both endothelial Map3k3I441M mutant juvenile mice and Map3k3I441M; Ptenfl/fl mice developed abnormal lesions with human CCM characteristics. In Map3k3I441M mice, the mutant promoted endothelial apoptosis, while activation of the PI3K (phosphatidylinositol 3-kinase) pathway was able to activate the downstream AKT (protein kinase B)/mTOR/p-S6 (phosphorylated S6 ribosomal protein) pathway and upregulate VEGFA (vascular endothelial growth factor A) expression, counteracting apoptosis, and facilitating lesion progression. The activation of PI3K signaling is required for Map3k3I441M to generate CCM-like lesions in adult mice. Finally, we demonstrated that rapamycin effectively inhibited the formation of lesions in the Map3k3I441M mice and Map3k3I441M; Ptenfl/fl mice.
Conclusions: Map3k3I441M heterozygous is sufficient to induce lesions in juvenile mice, while the additional activation of PI3K signaling is required for the effective formation of CCMs at the adult stage. The Map3k3I441M murine model provides a preclinical model for further mechanistic and therapeutic studies of CCMs.
期刊介绍:
Stroke is a monthly publication that collates reports of clinical and basic investigation of any aspect of the cerebral circulation and its diseases. The publication covers a wide range of disciplines including anesthesiology, critical care medicine, epidemiology, internal medicine, neurology, neuro-ophthalmology, neuropathology, neuropsychology, neurosurgery, nuclear medicine, nursing, radiology, rehabilitation, speech pathology, vascular physiology, and vascular surgery.
The audience of Stroke includes neurologists, basic scientists, cardiologists, vascular surgeons, internists, interventionalists, neurosurgeons, nurses, and physiatrists.
Stroke is indexed in Biological Abstracts, BIOSIS, CAB Abstracts, Chemical Abstracts, CINAHL, Current Contents, Embase, MEDLINE, and Science Citation Index Expanded.